NCT03233477

Brief Summary

Posner-Schlossman syndrome, or glaucomatocyclitic crisis, is a condition characterized by recurrent, acute attacks of mild, nongranulomatous, anterior uveitis accompanied by markedly elevated intraocular pressure. Most of patients are the 20 to 50-year-old young adults, with unilateral eye involvement. PSS was originally deemed benign, but is now recognized as a relatively rare cause of chronic secondary glaucoma,especially in patients with recurrent episodes. This relatively rare disease is likely the result of the infections of a variety of organisms, and the bulk of literature supports the cytomegalovirus (CMV) as the leading cause. This study is an observational study that does not interfere with the normal clinical diagnosis and treatment process. The investigators in this study focus on observing the clinical symptoms and outcome of PSS, analyzing the factors that affect the prognosis of PSS, studying the association of its pathogenesis with the psychological status and the behavioral types of PSS patients; exploring the relationship between infection (CMV, HSV, Hp) and PSS; and studying the changes of local and systemic cytokine expression and its significance in patients with PSS.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 31, 2014

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

July 22, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 28, 2017

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2024

Completed
Last Updated

October 14, 2020

Status Verified

October 1, 2020

Enrollment Period

10 years

First QC Date

July 22, 2017

Last Update Submit

October 11, 2020

Conditions

Keywords

Posner Schlossman Syndromecytokine expressioncytomegalovirus

Outcome Measures

Primary Outcomes (10)

  • demographic characteristics

    age, sex, education level, systemic disease, mental state

    up to 10 years

  • visual acuity

    uncorrected visual acuity and best corrected visual acuity

    up to 10 years

  • intraocular pressure

    Goldmann

    up to 10 years

  • slit-lamp examination

    anterior segment

    up to 10 years

  • fundus photograph

    analysis the morphology of optic nerve head

    up to 10 years

  • OCT

    zess

    up to 10 years

  • visual field

    Humphrey visual field

    up to 10 years

  • blood serum

    8ml

    up to 10 years

  • aqueous humor

    0.2ml

    up to 10 years

  • tissue

    iris and\& or trabecular meshwork tissue abandoned in the anti-glaucoma operation

    in the operation

Study Arms (3)

Posner-Schlossman Syndrome

Inclusion criteria: * Clinical diagnosis of Posner-Schlossman Syndrome * Able to communicate with doctor and understand this study Exclusion criteria: * Not be able to communicate with doctor and understand this study * One or more authorized investigators think he or she will suffer from any severe risks from the study

cataract

Inclusion criteria: * Clinical diagnosis of age-related cataract * Prepare for cataract operation * Open angle and intraocular pressure is normally at anytime * No family history of glaucoma Exclusion criteria: * Patients above 65 years old * With Secondary ocular hypertension * Have the history of receiving any ophthalmologic operation or anti-viral therapy * With diabetes mellitus * With autoimmune disease * Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month

primary open-angle glaucoma

Inclusion criteria: * Both eyes involved * Open angle * Progressive glaucomatous optic neuropathy * Specific visual field loss of glaucoma * Intraocular pressure above the up limit of normal people Exclusion criteria: * Patients above 65 years old * With Secondary ocular hypertension * Have the history of receiving any ophthalmologic operation or anti-viral therapy * With diabetes mellitus * With autoimmune disease * Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month

Eligibility Criteria

Age12 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All the patients that visit the Peking University Third Hospital from July 2014 to July 2019 and are diognosed as Posner-Schlossman Syndrome, age-related cataract, or primary open-angle glaucoma.

You may qualify if:

  • Volunteer to take part in this study and sign informed consent by oneself or the patient's legal representative
  • Clinical diagnosis of Posner-Schlossman Syndrome, age-related cataract, or primary open-angle glaucoma
  • Live in Beijing, China or being able to visit the Peking University Third Hospital every year after the beginning of the study or whenever the disease relapses

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Third Hosipital

Beijing, Beijing Municipality, 100191, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

serum, aqueous humor,iris,trabecular meshwork

Study Officials

  • Chun Zhang, PHD,MD

    Peking University Third Hospital

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 22, 2017

First Posted

July 28, 2017

Study Start

July 31, 2014

Primary Completion

July 31, 2024

Study Completion

July 31, 2024

Last Updated

October 14, 2020

Record last verified: 2020-10

Locations